Some treatments for MM that act by targeting specific cell surface antigens are already in clinical use, including treatments that target signaling lymphocytic activation molecule F7 (SLAMF7), CD38, CD138, CD56, CD200, CD40, BCMA, and CD74 [66,67,68,69,70,71,72,73]. Here, SDC1 is linked to Miyoshi myopathy.